Log in

Relevant bibliographies by topics / Hypolipidemic therapy / Journal articles

To see the other types of publications on this topic, follow the link: Hypolipidemic therapy.

Journal articles on the topic 'Hypolipidemic therapy'

Author: Grafiati

Published: 28 May 2022

Last updated: 30 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Hypolipidemic therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Boeva, Boeva O. I., Kokorin V. A. Kokorin, and Khripunova A. A. Khripunova. "Combined hypolipidemic therapy for mixed atherogenic dyslipidemia: review." Therapy 1_2022 (March 21, 2022): 162–73. http://dx.doi.org/10.18565/therapy.2022.1.162-173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Paoletti, R. "Evolution of hypolipidemic drug therapy." Atherosclerosis 144 (May 1999): 144. http://dx.doi.org/10.1016/s0021-9150(99)80556-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Benimetskaya, K. S., P. A. Atyukov, S. V. Astrakov, and Y. I. Ragino. "NEW POSSIBILITIES OF HYPOLIPIDEMIC THERAPY." Siberian Medical Review, no. 4 (2017): 65–81. http://dx.doi.org/10.20333/2500136-2017-4-65-81.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Manhas, Amit, and John A. Farmer. "Hypolipidemic therapy and cholesterol absorption." Current Atherosclerosis Reports 6, no. 2 (2004): 89–93. http://dx.doi.org/10.1007/s11883-004-0095-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Dlouha, Dana, Milan Blaha, Eva Rohlova, et al. "Multiplex Protein Biomarker Profiling in Patients with Familial Hypercholesterolemia." Genes 12, no. 10 (2021): 1599. http://dx.doi.org/10.3390/genes12101599.

Full text

Abstract:

Familial hypercholesterolemia (FH), is an autosomal dominant disorder caused by mutations in the LDLR, APOB, PCSK9, and APOE genes and is characterized by high plasma levels of total and low-density lipoprotein (LDL) cholesterol. Our study aimed to analyze the influences of two different therapies on a wide spectrum of plasma protein biomarkers of cardiovascular diseases. Plasma from FH patients under hypolipidemic therapy (N = 18; men = 8, age 55.4 ± 13.1 years) and patients under combined long-term LDL apheresis/hypolipidemic therapy (N = 14; men = 7; age 58.0 ± 13.6 years) were analyzed in

APA, Harvard, Vancouver, ISO, and other styles

6

Cignarella, Andrea, Stefano Bellosta, Alberto Corsini, and Chiara Bolego. "Hypolipidemic therapy for the metabolic syndrome." Pharmacological Research 53, no. 6 (2006): 492–500. http://dx.doi.org/10.1016/j.phrs.2006.03.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kuchmin, Alexey N., Mikhail B. Nagorny, Anatoly M. Grachev, and Elena V. Smirnova. "Modern prospects of targeted hypolipidemic therapy." Bulletin of the Russian Military Medical Academy 25, no. 2 (2023): 275–88. http://dx.doi.org/10.17816/brmma321350.

Full text

Abstract:

ABSTRACT. This article analyzes new approaches to reducing atherogenic lipoproteins using lipid-lowering drugs with innovative mechanisms of action. It examines the role of different groups of lipid-lowering drugs in the overall range of modern methods for correcting lipid metabolism disorders. The significance of statins as a foundational therapy in primary and secondary prevention of cardiovascular diseases with atherosclerotic origins is emphasized. The article presents research findings on a new target in lipid-lowering therapy, namely the proprotein convertase of subtilisin/kexin type 9 (

APA, Harvard, Vancouver, ISO, and other styles

8

Sukovatykh, B. S., V. I. Vishnevsky, N. V. Bolomatov, et al. "The eff ect of standard lipid-lowering therapy and the type of stent on the course of the atherosclerotic process in the coronary arteries in patients with hereditary hypercholesterolemia and acute coronary syndrome." Clinical Medicine (Russian Journal) 102, no. 8 (2025): 641–46. https://doi.org/10.30629/0023-2149-2024-102-8-641-646.

Full text

Abstract:

Objective. Тo study the impact of standard hypolipidemic therapy and stent type on the progression of atherosclerosis in coronary arteries in patients with familial hypercholesterolemia and acute coronary syndrome. Material and methods. Analyzed treatment results of 100 patients with familial hypercholesterolemia and acute coronary syndrome, divided into two equal groups. Group 1 received bare-metal stents, while Group 2 received drug-eluting stents. All patients were prescribed standard hypolipidemic therapy to reduce restenosis risk and normalize lipid profiles. Immediate postoperative outco

APA, Harvard, Vancouver, ISO, and other styles

9

Diachuk, Dmytro D., Galina Z. Moroz та Oleksandr M. Tkalenko. "CORRECTION OF DYSLIPIDEMIA: HISTORICAL ASPECT AND CURRENT VIEW OF THE PROBLEM (REVIEW, PART IІ)". Clinical and Preventive Medicine, № 4 (30 квітня 2025): 134–44. https://doi.org/10.31612/2616-4868.4.2025.17.

Full text

Abstract:

Aim. To summarize scientific publications, clinical guidelines (CG) regarding the development of standardized approaches to the correction of dyslipidemia and the introduction of new hypolipidemic drugs at the current stage. Materials and methods. The analysis and generalization of scientific articles, clinical guidelines on the introduction of standardized approaches to the correction of dyslipidemia at the current stage and the use of new hypolipidemic drugs for the prevention and treatment of cardiovascular diseases (CVD) were carried out. Methods were used: systematic approach, biblioseman

APA, Harvard, Vancouver, ISO, and other styles

10

Singh, Roy Sukbir, and Hendrika A. Silitonga. "Hypolipidemic Effects Of Aloe Vera (Aloe Vera L.)." International Journal of Biomedical Herbal Medicine 1, no. 1 (2021): 15–28. http://dx.doi.org/10.46880/ijbhm.v1i1.732.

Full text

Abstract:

Background: Chronic hyperlipidemia is a trigger factor for serious diseases, one of which is atherosclerosis. Lipid profile disorders in the form of increased total cholesterol, LDL and decreased HDL levels are believed to be one of the major triggering factors for cardiovascular disease. One of the treatments for hyperlipidemia in addition to using conventional therapy can also be with traditional treatments such as aloe vera (Aloe Vera L). The content of glucomannan in aloe vera is believed to act as a hypolipidemic agent. Method: This paper uses a literature study or literature review of re

APA, Harvard, Vancouver, ISO, and other styles

11

Tyurenkov, I. N., Yu S. Knyazeva, L. M. Ganicheva, and N. Sh Kaysheva. "Problems of pharmaceutical provision of population with hypolipidemic drugs: the case of the Volgograd region (the Russian Federation)." Pharmacy & Pharmacology 8, no. 1 (2020): 65–73. http://dx.doi.org/10.19163/2307-9266-2020-8-1-65-73.

Full text

Abstract:

The aim of the study is to study the regional hypolipidemic drugs market, external and internal factors affecting their level of consumption, including the information awareness of the final customers about this pharmacotherapeutic group and the adherence to treatment with these drugs.Materials and methods. The study was carried out using the methods of SWOT and STEP-analyses to assess the factors affecting the consumption of the studied group of drugs, as well as the questionnaire method of final customers and assessing their compliance using the Morisky-Green questionnaire.Results. The influ

APA, Harvard, Vancouver, ISO, and other styles

12

Lazebnik, L. B., L. A. Zvenigorodskaya, N. G. Samsonova, E. A. Cherkasova, and N. V. Melnikova. "Hypolipidemic therapy in patients with non-alcoholic fatty liver disease." CardioSomatics 1, no. 1 (2010): 38–45. http://dx.doi.org/10.26442/cs44961.

Full text

Abstract:

Dyslipidemia is currently accepted to be one of the major risk factor for cardiovascular diseases and atherosclerosis. There is no question that the liver plays an important role in the development of atherogenic dyslipidemia and it is simultaneously a target organ, which results in the development of non-alcoholic fatty liver disease (NAFLD). The latter limits the feasibilities of adequate hypolipidemic therapy, thus increasing the cardiovascular risks. There is a need to use hepatoprotectors when atherogenic dyslipidemia in a patient with documented NAFLD is treated with statins and fibrates

APA, Harvard, Vancouver, ISO, and other styles

13

Krizshanovsky, S. P., B. I. Geltser, T. A. Kuznetsova, E. V. Persiyanova, and T. S. Zaporozhets. "The effectiveness of combined therapy of dyslipidemia by atorvastatin and biologycally active substances from marine hydrobionts." Russian Journal of Biotherapy 16, no. 2 (2017): 97–102. http://dx.doi.org/10.17650/1726-9784-2017-16-2-97-102.

Full text

Abstract:

Introduction. The perspective direction in therapy of dyslipidemia (DLP) is a complex application of biologycally active substances from marine hydrobionts. Objective. The purpose of research - to compare the lipidcorrective action of preparates based on biologically active substances from marine hydrobionts - fukolam and maristim - individually and in combination with atorvastatin in patients with DLP. Materials and methods. 250patients with DLP and 40 healthy donors were included in research. As medicines atorvastatin, fukolam, maristim were used. In the blood serum the levels of lipid spect

APA, Harvard, Vancouver, ISO, and other styles

14

Oynotkinova, O. S., E. L. Nikonov, T. Y. Demidova, et al. "Changes in the intestinal microbiota as a risk factor for dyslipidemia, atherosclerosis and the role of probiotics in their prevention." Terapevticheskii arkhiv 92, no. 9 (2020): 94–101. http://dx.doi.org/10.26442/00403660.2020.09.000784.

Full text

Abstract:

The review presents an analysis of studies on the role of the intestinal microbiota and microbiome in lipid metabolism and the development of dyslipidemia, atherosclerosis and cardiovascular diseases. The role of the intestine as a metabolic organ with a multifactorial strain evolution, involved in lipid metabolism, cholesterol homeostasis and enterohepatic circulation is shown. The influence of microbial imbalance on the development of dyslipidemia and atherosclerosis is considered. Special attention is paid to preventive therapy with hypolipidemic probiotics. It is shown that the use of prob

APA, Harvard, Vancouver, ISO, and other styles

15

Kudina, Ekaterina V., Irina A. Samkova, and Vera N. Larina. "Hypolipidemic therapy: evidence-based effectiveness and new perspectives." Consilium Medicum 22, no. 10 (2020): 55–60. http://dx.doi.org/10.26442/20751753.2020.10.200292.

Full text

Abstract:

Background. Hyperlipidemia is one of the most important risk factors for the onset and progression of cardiovascular diseases. Currently, several classes of drugs are used in lipid-lowering therapy, which have proven their effectiveness over the past decades. However, in a number of patients there is an intolerance to these drugs or it is not possible to achieve the target levels of the lipid spectrum against the background of the use of maximum doses and combination therapy. This dictates the need to create new lipid-lowering drugs. Aim. To present data on the proven efficacy of widely used d

APA, Harvard, Vancouver, ISO, and other styles

16

Shevchenko, A. О. "HYPOLIPIDEMIC THERAPY IN PATIENTS AFTER HEART TRANSPLANTATION: STATINS." Russian Journal of Transplantology and Artificial Organs 18, no. 2 (2016): 171–76. http://dx.doi.org/10.15825/1995-1191-2016-2-171-176.

Full text

Abstract:

Statins should be used as a part of standard therapy in patients after heart transplantation. The effectiveness of statins is associated not only with their hypolipidemic action, but also with their immunomodulatory and antineoplastic properties. Statin therapy initiated early after heart transplantation improves the shortand long-term prognosis and outcomes, leading to a reduction in the incidence of cardiac allograft vasculopathy, acute rejection, and cancer.

APA, Harvard, Vancouver, ISO, and other styles

17

Tsibulskaya, N. Yu, E. I. Kharkov, and M. M. Petrova. "HYPOLIPIDEMIC THERAPY BY STATINS IN ACUTE CORONARY SYNDROME." Siberian Medical Review, no. 6 (2018): 22–32. http://dx.doi.org/10.20333/2500136-2018-6-22-32.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Suica, Viorel I., Elena Uyy, Luminita Ivan, et al. "Cardiac Alarmins as Residual Risk Markers of Atherosclerosis under Hypolipidemic Therapy." International Journal of Molecular Sciences 23, no. 19 (2022): 11174. http://dx.doi.org/10.3390/ijms231911174.

Full text

Abstract:

Increased levels of low-density lipoproteins are the main risk factor in the initiation and progression of atherosclerosis. Although statin treatment can effectively lower these levels, there is still a residual risk of cardiovascular events. We hypothesize that a specific panel of stress-sensing molecules (alarmins) could indicate the persistence of silent atherosclerosis residual risk. New Zealand White rabbits were divided into: control group (C), a group that received a high-fat diet for twelve weeks (Au), and a treated hyperlipidemic group with a lipid diet for eight weeks followed by a s

APA, Harvard, Vancouver, ISO, and other styles

19

Sandler, Yu G., and E. V. Vinnitskaya. "Hypolipidemic Therapy in Patients with Chronic Liver Diseases: What Should a Gastroenterologist Know." Effective Pharmacotherapy 17, no. 28 (2021): 36–45. http://dx.doi.org/10.33978/2307-3586-2021-17-28-36-45.

Full text

Abstract:

Dyslipidemia is one of the main risk factors for the development of cardiovascular diseases (CVD), which remain the leading cause of death worldwide. Lipid level control is the most effective strategy for the prevention of CVD and its complications (CVC). Statins are the first-line drugs of hypolipidemic therapy. Dyslipidemia is often found in patients with chronic liver diseases (CLD). From a clinical point of view, a number of CLD have an increased risk of CVD. Due to insufficient awareness of doctors about the possibilities of using statin and non-statin lipid-lowering therapy in patients w

APA, Harvard, Vancouver, ISO, and other styles

20

Spáčil, Jiří, Richard Ceška, Josef Sobra, Jan Petrášek, and Jiří Spáčil. "Decreasing Common Carotid Artery Intimal Thickness During Hypolipidemic Therapy." Angiology 48, no. 9 (1997): 761–67. http://dx.doi.org/10.1177/000331979704800902.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Sumarokov, A. B. "Inclisiran — lipid-lowering drug using RNA therapy. Hypolipidemic potential." Kardiologicheskii vestnik 17, no. 4 (2022): 32. http://dx.doi.org/10.17116/cardiobulletin20221704132.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Benetos, Georgios, Spyros Galanakos, Iosif Koutagiar, et al. "Carotid Artery Temperature Reduction with Statin Therapy in Patients with Familial Hyperlipidemia Syndromes." Journal of Clinical Medicine 10, no. 21 (2021): 5008. http://dx.doi.org/10.3390/jcm10215008.

Full text

Abstract:

Background: Microwave radiometry (MWR) assesses non-invasive carotid artery temperatures reflecting inflammation. In the present study, we aimed to investigate the impact of hypolipidemic therapy either with simvastatin or with combination simvastatin plus ezetimibe on carotid artery temperatures of patients with familial hyperlipidemia syndromes (FHS). Methods: Consecutive patients with diagnosis of either familial heterozygous hypercholesterolemia (heFH) or familial combined hyperlipidemia (FCH) were included in the study. Patients were assigned to either simvastatin 40 mg or simvastatin 40

APA, Harvard, Vancouver, ISO, and other styles

23

Saydalev Rustam Saydalievich. "Modern aspects of the application of antiplatelet and hypolipidemic therapy in ischemic heart disease after coronary artery stenting." GSC Biological and Pharmaceutical Sciences 15, no. 3 (2021): 212–17. http://dx.doi.org/10.30574/gscbps.2021.15.3.0150.

Full text

Abstract:

In this article it will be discussed actual issues and modern problems of the ischemic disease of the heart, antiplatelet therapy, its effects, hypolipidemic therapy, indications, counter indications, potential side effects as well as, successful management strategies after percutaneous coronary intervention following with drug eluted stents.

APA, Harvard, Vancouver, ISO, and other styles

24

Saydalev, Rustam Saydalievich. "Modern aspects of the application of antiplatelet and hypolipidemic therapy in ischemic heart disease after coronary artery stenting." GSC Biological and Pharmaceutical Sciences 15, no. 3 (2021): 212–17. https://doi.org/10.5281/zenodo.5060673.

Full text

Abstract:

In this article it will be discussed actual issues and modern problems of the ischemic disease of the heart, antiplatelet therapy, its effects, hypolipidemic therapy, indications, counter indications, potential side effects as well as, successful management strategies after percutaneous coronary intervention following with drug eluted stents. 

APA, Harvard, Vancouver, ISO, and other styles

25

Aitbaev, K. A., I. T. Murkamilov, and V. V. Fomin. "Hypolipidemic Therapy and Chronic Kidney Disease: Effects on Cardiovascular Risks and Renal Dysfunction." Kardiologiia 59, no. 2 (2019): 79–87. http://dx.doi.org/10.18087/cardio.2019.2.10231.

Full text

Abstract:

Steady increase in the prevalence of chronic kidney disease (CKD) is a serious public health problem, since CKD potentially leads to the development of end-stage renal disease (ESRD) that requires high-cost replacement therapy and is closely associated with increased risk of developing cardiovascular diseases (CVD), which are the cause of death in most patients. Progression of renal dysfunction and development of CVD are significantly affected by hyper- and dyslipidemia. This review contains results of studies evaluating the effect of hypolipidemic therapy on reduction of cardiovascular risk a

APA, Harvard, Vancouver, ISO, and other styles

26

Podzolkov, V. I., E. A. Gladysheva, and A. E. Bragina. "Moxonidin in combined therapy of metabolic syndrome." "Arterial’naya Gipertenziya" ("Arterial Hypertension") 13, no. 4 (2007): 246–49. http://dx.doi.org/10.18705/1607-419x-2007-13-4-246-249.

Full text

Abstract:

The paper presents the results of 24-weeks follow-up and treatment patients with metabolic syndrome. It shows antihypertensive effect of imidazoline-receptor agonist moxonidine and hypolipidemic effect of micronized fenofibrate in patients with metabolic syndrome. The combination demonstrate synergic action on carbohydrate and uric acid metabolism. Thus, it can significantly decrease the level of cardio-vascular risk (SCORE) in patients with metabolic syndrome.

APA, Harvard, Vancouver, ISO, and other styles

27

Гальцова, О. А., and А. Г. Захаренко. "Hypolipidemic Pharmacotherapy from the Latest Recommendations." Рецепт, no. 1 (March 17, 2020): 97–107. http://dx.doi.org/10.34883/pi.2020.23.1.010.

Full text

Abstract:

Сердечно-сосудистые заболевания (ССЗ) уносят каждый год более 4 млн жизней. В развитии ССЗ, связанных с атеросклерозом, доказана роль таких факторов, как сахарный диабет (СД), дислипидемия, ожирение. В связи с этим очень важны профилактика и лечение ССЗ и выявление групп риска, угрожаемых по развитию атеросклероза. Доказана роль уровня холестерина (ХС) липопротеидов низкой плотности (ЛПНП), который является ключевым фактором в развитии атеросклероза. В то же время необходимо провести оценку показаний у пациентов различных групп риска по шкале SCORE для решения вопроса о необходимости назначени

APA, Harvard, Vancouver, ISO, and other styles

28

Lasebnik, L. B., L. N. Chikhireva, O. A. Chikhirev, and E. D. Li. "Choice of antihyprtensive therapy at varios stages of metabolically associated lever disease." Experimental and Clinical Gastroenterology, no. 11 (March 26, 2024): 52–61. http://dx.doi.org/10.31146/1682-8658-ecg-219-11-52-61.

Full text

Abstract:

Metabolic dysfunction associated steatatotic liver disease (MASLD) and hypertension are two chronic progressive diseases that require a comprehensive approach. The article discusses approaches to the appointment of hypotensive and hypolipidemic therapy in patients with MASLD, depending on the stage of the disease.

APA, Harvard, Vancouver, ISO, and other styles

29

Piťha, Jan. "How to create cooperative patient for antihypertensive and hypolipidemic therapy." Vnitřní lékařství 63, no. 4 (2017): 272–76. http://dx.doi.org/10.36290/vnl.2017.055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Stefanutti, C., C. Morozzi, and S. Di Giacomo. "New Clinical Perspectives of Hypolipidemic Drug Therapy in Severe Hypercholesterolemia." Current Medicinal Chemistry 19, no. 28 (2012): 4861–68. http://dx.doi.org/10.2174/092986712803341485.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Balandina, Y., Y. Tarlovskaya, and N. Maksimchuk-Kolobova. "Hypolipidemic therapy in patients with a very high cardiovascular risk." Atherosclerosis 235, no. 2 (2014): e260. http://dx.doi.org/10.1016/j.atherosclerosis.2014.05.778.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Zucker, M. L., C. Trowbńdge, P. Krehbiel, B. Jackson, S. B. Chernoff, and C. A. Dujovne. "Platelet Function in Hypercholesterolemics before and after Hypolipidemic Drug Therapy." Pathophysiology of Haemostasis and Thrombosis 16, no. 1 (1986): 57–64. http://dx.doi.org/10.1159/000215271.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Koval, S. M., L. A. Rieznik, O. V. Mysnychenko, and M. Y. Penkova. "Effectiveness of a fixed combination of empagliflozin with metformin in reduction of cardiovascular risk in patients with uncontrolled arterial hypertension and decompensated type 2 diabetes mellitus." Ukrainian Therapeutical Journal, no. 3 (October 7, 2024): 12–19. http://dx.doi.org/10.30978/utj2024-3-12.

Full text

Abstract:

Objective is to study the effectiveness of a fixed combination of empagliflozin and metformin in reducing cardiovascular risk in patients with uncontrolled arterial hypertension (AH) and decompensated type 2 diabetes mellitus (DM). Materials and methods. 36 patients with uncontrolled AH and decompensated type 2 diabetes mellitus aged 45 to 60 were examined. Before inclusion in the study, all patients received standard antihypertensive (angiotensin‑converting enzyme (ACE) inhibitor or angiotensin‑II receptor blocker (ARB) in combination with a calcium channel blocker and a thiazide‑like diureti

APA, Harvard, Vancouver, ISO, and other styles

34

Matіukha, Larysa, and Bohdan Smal. "Factor of Basic Pharmacologic Therapy in DSME Applying." Family Medicine, no. 5-6 (March 15, 2021): 75–78. http://dx.doi.org/10.30841/2307-5112.5-6.2020.225460.

Full text

Abstract:

The objective: to investigate the influence of the scheme of basic pharmacologic therapy on the dynamics of carbohydrate and lipid metabolism in a group of patients with type 2 diabetes on the background of the use of group DSME. Materials and methods. The study was performed on the basis of the Department of Family Medicine and Outpatient Care within the territorial boundaries of the Kyiv agglomeration. The study included 117 patients with type 2 diabetes. The study group of patients was randomly divided into a groups of classroom training (38 people), a group of remote training (39 peo

APA, Harvard, Vancouver, ISO, and other styles

35

Khokonova, Tamara Muratovna, Zaira Feliksovna Kharaeva, Rustam Khasanovich Keshokov, Sofiat Khasenovna Sizhazheva, and Svetlana Sergeevna Solyanik. "Dynamics of central hemodynamic parameters and cytokine levels in patients with chronic kidney disease and arterial hypertension during combination therapy." Spravočnik vrača obŝej praktiki (Journal of Family Medicine), no. 12 (December 20, 2020): 46–56. http://dx.doi.org/10.33920/med-10-2012-06.

Full text

Abstract:

The effect of antihypertensive and hypolipidemic therapy with the use of a fixed combination of amlodipine, lisinopril and rosuvastatin on the parameters of cytokines (the level of the proinflammatory cytokine - interleukin-1β, anti-inflammatory cytokine - interleukin-10, ligand CD40 (CD40L)), central aortic pressure, arterial stiffness and the value of albuminuria in patients with stage 3 chronic kidney disease, both in combination with arterial hypertension (AH) of 1-2 degrees, and without it, and in patients with coronary artery disease in combination with AH. The results of the study allow

APA, Harvard, Vancouver, ISO, and other styles

36

Murad, Shah, Saima Rafique, Abrar Umar, Manal Raouf Mahar, M. Hyder Awan, and Sibghatullah Sangi. "HERBAL COMMUNITY: Another consideration about Pharmacognosy." Pharmaceutics and Pharmacology Research 3, no. 2 (2020): 01–03. http://dx.doi.org/10.31579/2693-7247/009.

Full text

Abstract:

The metabolic disorders are main and increasing public-health and clinical challenge worldwide because of urbanization, excessive energy intake, increasing obesity, and sedentary life styles. According to International Diabetes Federation (IFD) diabetes is one of the major metabolic disorders and a dangerous risk factor for heart problems. Twenty five percent of the world’s adults have metabolic disorders. Recently in year 2013 the American Heart Association also reported that adults have abnormal serum lipid profile. Allopathic drugs used as hypolipidemic agents have number of unwanted effect

APA, Harvard, Vancouver, ISO, and other styles

37

Kuznetsova, N. O., F. E. Mammedzade, M. A. Podyanov, E. A. Shobonova, P. Sh Chomakhidze, and Ph Yu Kopylov. "Evaluation of the Effectiveness of Lipid Lowering Therapy in Real Clinical Practice." Doctor.Ru 23, no. 8 (2024): 41–46. https://doi.org/10.31550/1727-2378-2024-23-8-41-46.

Full text

Abstract:

Aim. To evaluate hypolipidemic therapy in real clinical practice, the frequency of achieving target lipid values and the reasons for ineffective treatment of dyslipidemia. Design. Retrospective prospective nonrandomized single-center continuous study. Materials and methods. From 8655 persons referred to any department of Sechenov University, we selected those with documented dyslipidemia and patients prescribed or receiving lipid-lowering therapy. In the end, we selected 3812 patients. In the course of our work, we called all patients. Among those who agreed to participate in the study, we int

APA, Harvard, Vancouver, ISO, and other styles

38

Okunevich, Irina Viktorovna, Lyudmila Konstantinovna Khnychenko, and Petr Dmitriyevich Shabanov. "Influence of hypoxen on the data changing of lipid metabolsim in the experimantal dislipoproteinemia." Reviews on Clinical Pharmacology and Drug Therapy 12, no. 3 (2014): 26–29. http://dx.doi.org/10.17816/rcf12326-29.

Full text

Abstract:

The hypolipidemic efficiency of antihypoxant hypoxen in the experimantal conditions of alimantary dislipoproteinemia (DLP) in rats and guinea pigs in comparison with lipid-lowering drugs gemfibrozyl and probucol in doclinic investigation was studied. The alimantary models of DLP were created by feeding of rats and guinea pigs of hypercholesterol diet (rich content of food cholesterol, the plant and animal lipids, vitamin D2) during 30 days. The concentration of lipid oxidative products in serum and indicators of lipid metabolism (content of TCh, TG, HDL-Ch) in blood and liver were analysed. Th

APA, Harvard, Vancouver, ISO, and other styles

39

Parkhomenko, O. M., A. O. Stepura, Y. M. Lutay, O. I. Irkin, and D. O. Bilyi. "Effect of early hypolipidemic therapy of different intensity on endothelial function in patients with acute myocardial infarction with ST segment elevation." Ukrainian Journal of Cardiology 26, no. 6 (2020): 27–38. http://dx.doi.org/10.31928/1608-635x-2019.6.2738.

Full text

Abstract:

The aim – to evaluate the effect of different hypolipidemic therapy on changes in endothelial function in patients with acute myocardial infarction with ST segment elevation (STEMI).Materials and methods. The study enrolled 135 patients with STEMI within the 12 hours of symptoms onset (average 4.7±1.0) who were admitted to the intensive care unit at NSC «M.D. Strazhesko Institute of Cardiology». Patients were distributed into 4 groups by envelope method. At the enrolment to the hospital patients were prescribed hypolipidemic therapy till the procedure of revascularization – percutaneous corona

APA, Harvard, Vancouver, ISO, and other styles

40

Grosu, Cristina, Alexandra Mastaleru, Otilia Nita, et al. "Effects of Statin Therapy in Patients with Stroke and Atheromatosis." Revista de Chimie 69, no. 12 (2019): 3698–701. http://dx.doi.org/10.37358/rc.18.12.6822.

Full text

Abstract:

Recent studies have shown that as the average life expectancy increases, more people will suffer a stroke in their lives, diminishing their quality of life. Secondary stroke prevention involves reducing the cardiovascular risk factors and administering medication for preventive purposes, where statins play an important role. The purpose of this study is to highlight the correlations of statins dosage with cardiovascular risk factors (atheromatosis, uric acid value, obesity, etc), in stroke patients receiving hypolipidemic treatment with statins.

APA, Harvard, Vancouver, ISO, and other styles

41

Khalimov, Yury Shavkatovich, and Alla Vsevolodovna Rudakova. "A cost-effectiveness analysis of intensive therapy of type 2 diabetes mellitus (results of Steno-2 study)." Diabetes mellitus 14, no. 2 (2011): 116–20. http://dx.doi.org/10.14341/2072-0351-5647.

Full text

Abstract:

Intensive combined therapy including modification of the lifestyle, intake of metformin and/or sulfonylureas, insulin treatment in the absence ofadequate HbAc1 control, hypolipidemic, early antihypertensive and antithrombotic therapy not only decreases the frequency of DM2 complicationsbut also reduces the total cost of the treatment (1.8 times compared with traditional therapy). Reduction in cardiovascular mortality achieved inSTENO-2 was due to intense control of risk factors at early stages of therapy with the use of modified release gliclazide (Diabeton MV). This treatmentis considered to

APA, Harvard, Vancouver, ISO, and other styles

42

Ali, Shima Mahmoud, Fatma E. Salem, Mohammad M. Aboulwafa, and Riham M. Shawky. "Hypolipidemic activity of lactic acid bacteria: Adjunct therapy for potential probiotics." PLOS ONE 17, no. 6 (2022): e0269953. http://dx.doi.org/10.1371/journal.pone.0269953.

Full text

Abstract:

Background Individuals with hyperlipidemia are two times more likely to develop atherosclerotic cardiovascular disease (ASCVD) as opposed to those with controlled serum total cholesterol (TC) levels. Considering the documented adverse events of the current lipid-lowering medications which ultimately affect patient’s compliance, substantial efforts have been made to develop new therapeutic strategies. Probiotics, on the other hand, are reported to have lipid-lowering activity with the added benefit of being generally well-tolerated making it an appealing adjuvant therapy. Methods A total of fif

APA, Harvard, Vancouver, ISO, and other styles

43

Heller, F. R. "Prevention Of Cardiovascular Events By Hypolipidemic Therapy Evidence-Based Medicine Criteria." Acta Clinica Belgica 54, no. 5 (1999): 299–301. http://dx.doi.org/10.1080/17843286.1999.11754249.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Karshina, O., E. Mohammad, R. Inarkiev, S. Fazilova, A. Khankishiev, and I. Sabirov. "Metabolically Associated Steatotic Liver Disease and the Possibilities of Using Antihypertensive and Hypolipidemic Medications." Bulletin of Science and Practice 11, no. 2 (2025): 188–204. https://doi.org/10.33619/2414-2948/111/24.

Full text

Abstract:

Metabolically associated steatotic liver disease (MASLD) is one of the most common liver pathologies. Metabolically associated steatotic liver disease is closely linked to metabolic syndrome, including obesity, type 2 diabetes, dyslipidemia, and arterial hypertension, making it not only a gastroenterological issue but also a significant aspect of cardiometabolic diseases. An important task is finding effective treatments aimed at improving the condition of such patients. In recent years, antihypertensive and hypolipidemic drugs have gained attention as potential means for correcting the disord

APA, Harvard, Vancouver, ISO, and other styles

45

Stanulovic, Vid, Mirjana Djeric, and Jovan Popovic. "Clinical trials of statins and fibrates: A meta-analysis." Medical review 59, no. 5-6 (2006): 213–18. http://dx.doi.org/10.2298/mpns0606213s.

Full text

Abstract:

Introduction. Several clinical trials of hypolipidemics showed a decrease in mortality by 30-40%, while others showed detrimental or no effects. The question remains: which trial should be the basis of clinical decision making in the choice of hypolipidemic therapy? Material and methods. Meta-analysis is a method for combining research results of several studies. Effects of statins and fibrates with respect to placebo, were assessed by systematic literature review and meta-analysis. Medline and CENTRAL databases were searched using the following keywords: hyperlipoproteinemia, hypolipidemic ag

APA, Harvard, Vancouver, ISO, and other styles

46

Goumas, Georgios S. "Is There Evidence-based Hypolipidemic Treatment with Clinical Benefit beyond Statins?" Angiology 60, no. 1 (2008): 93–98. http://dx.doi.org/10.1177/0003319708326452.

Full text

Abstract:

Aggressive therapy with statins to lower the low density lipoprotein cholesterol decreases cardiovascular events. Nevertheless, administration of the highest approved statin dose only offers limited additional benefit at the expense of an increased incidence of side effects. Therefore, novel compounds that further reduce the low-density lipoprotein cholesterol and at the same time have beneficial effects on other lipid parameters when added to statin therapy are under investigation. Nicotinic acid lowers the levels of the low-density lipoprotein cholesterol and triglycerides while raising the

APA, Harvard, Vancouver, ISO, and other styles

47

Siluaynov, V. V. "THE USE OF MEDOSTATIN IN COMPLEX TREATMENT OF ISCHEMIC STROKE." Health and Ecology Issues, no. 3 (September 28, 2009): 68–71. http://dx.doi.org/10.51523/2708-6011.2009-6-3-15.

Full text

Abstract:

Ischemia is most frequent cause of stroke. Atherosclerosis of aorta and carotids is factor of rise of development of ischemic stroke.This time it is shown that intensive hypolipidemic therapy is important part of treatment both primary and repeated stroke.Hypolipidemic activity,safety and tolerance of medostatin in patients with ischemic stroke are investigated.

APA, Harvard, Vancouver, ISO, and other styles

48

Gogolashvili, N. G. "Moderate-intensity statin therapy. Efficacy and safety issues." Russian Journal of Cardiology 28, no. 6 (2023): 5485. http://dx.doi.org/10.15829/1560-4071-2023-5485.

Full text

Abstract:

High rates of cardiovascular (CV) morbidity and mortality dictates the need to determine approaches to therapy that would reduce complications rate and improve patient’s prognosis. High-intensity statin therapy is an integral part of the treatment of patients with high and very high cardiovascular risk. At the same time, there is a large cohort of patients who would benefit from moderate intensity statin therapy. In the present article we have summarized available data on hypolipidemic effects, pleiotropic effects and role of moderate intensity statin therapy, atorvastatin particularly, in red

APA, Harvard, Vancouver, ISO, and other styles

49

Ostroumova, O. D., I. A. Alyautdinova, T. M. Ostroumova, E. Yu Ebzeeva, and E. E. Pavleeva. "Choosing optimal cerebroprotection strategy for polymorbid stroke patient." Medical alphabet, no. 2 (June 12, 2020): 15–19. http://dx.doi.org/10.33667/2078-5631-2020-2-15-19.

Full text

Abstract:

The clinical example in this article shows the successful experience of using the neuroprotective agent citicoline (Noocyl) in a comorbid patient after an ischemic stroke with motor and cognitive impairment in combination with antihypertensive, hypolipidemic, and antiplatelet therapy. High efficiency and good tolerance of this drug, the ability to improve cognitive and motor processes are shown.

APA, Harvard, Vancouver, ISO, and other styles

50

Uthirapathy, Subasini, and Tara F. Tahir. "Withania Somnifera: Correlation of Phytoconstituents with Hypolipidemic and Cardioprotective Activities." ARO-THE SCIENTIFIC JOURNAL OF KOYA UNIVERSITY 9, no. 2 (2021): 15–21. http://dx.doi.org/10.14500/aro.10844.

Full text

Abstract:

Withania somnifera (WS) (Dunal) or Ashwagandha is a well-known hypolipidemic herb and antioxidant. In this study, 75% ethanolic extract of WS is attempted to evaluate the cardioprotective activity of isoproterenol-induced cardiotoxicity and hypolipidemic activity in Triton WR 1339-induced hyperlipidemia. In addition, phytochemical evaluation of the same extracts analyzed by gas chromatography–mass spectrometer (GC–MS). This study found that 7 days of therapy with WS extracts at 1000 mg/kg b.wt. reduced cholesterol by 76%, low-density lipoprotein (LDL) by 71%, and TAG by 12% (P < 0.05). Furt

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!